Eintrag weiter verarbeiten
SARS-CoV-2 mRNA Vaccine Effectiveness in Health Care Workers by Dosing Interval and Time Since Vaccination: Test-Negative Design, British Columbia, Canada
Gespeichert in:
| Zeitschriftentitel: | Open Forum Infectious Diseases |
|---|---|
| Personen und Körperschaften: | , , , , , |
| In: | Open Forum Infectious Diseases, 9, 2022, 5 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Oxford University Press (OUP)
|
| Schlagwörter: |
| author_facet |
El Adam, Shiraz Zou, Macy Kim, Shinhye Henry, Bonnie Krajden, Mel Skowronski, Danuta M El Adam, Shiraz Zou, Macy Kim, Shinhye Henry, Bonnie Krajden, Mel Skowronski, Danuta M |
|---|---|
| author |
El Adam, Shiraz Zou, Macy Kim, Shinhye Henry, Bonnie Krajden, Mel Skowronski, Danuta M |
| spellingShingle |
El Adam, Shiraz Zou, Macy Kim, Shinhye Henry, Bonnie Krajden, Mel Skowronski, Danuta M Open Forum Infectious Diseases SARS-CoV-2 mRNA Vaccine Effectiveness in Health Care Workers by Dosing Interval and Time Since Vaccination: Test-Negative Design, British Columbia, Canada Infectious Diseases Oncology |
| author_sort |
el adam, shiraz |
| spelling |
El Adam, Shiraz Zou, Macy Kim, Shinhye Henry, Bonnie Krajden, Mel Skowronski, Danuta M 2328-8957 Oxford University Press (OUP) Infectious Diseases Oncology http://dx.doi.org/10.1093/ofid/ofac178 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>One- and two-dose mRNA vaccine effectiveness (VE) estimates against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by dosing interval and time since vaccination were assessed among healthcare workers (HCWs) in publicly funded acute and community (nonresidential) healthcare facilities in British Columbia, Canada.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>A test-negative design was used with controls matched to cases (6:1) on epidemiological week of SARS-CoV-2 test date. mRNA vaccination was defined by receipt of the first dose ≥21 days or second dose ≥14 days before the test date. HCWs ≥18 years old tested for SARS-CoV-2 between epi-weeks 3 and 39 (January 17–October 2, 2021) were included, when varying dosing intervals and a mix of circulating variants of concern contributed, including Delta dominance provincially from epi-week 31 (August 1).</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Single- and two-dose analyses included 1265 and 1246 cases, respectively. The median follow-up period (interquartile range) was 49 (34–69) days for single-dose and 89 (61–123) days for two-dose recipients, with 12%, 31%, and 58% of second doses given 3–5, 6, or ≥7 weeks after the first. Adjusted mRNA VE against SARS-CoV-2 was 71% (95% CI, 66%–76%) for one dose and 90% (95% CI, 88%–92%) for two doses, similar to two heterologous mRNA doses (92%; 95% CI, 86%–95%). Two-dose VE remained &gt;80% at ≥28 weeks post–second dose. Two-dose VE was consistently 5%–7% higher with a ≥7-week vs 3–5-week interval between doses, but with overlapping confidence intervals.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Among HCWs, we report substantial single-dose and strong and sustained two-dose mRNA vaccine protection, with the latter maintained for at least 7 months. These findings support a longer interval between doses, with global health and equity implications.</jats:p> </jats:sec> SARS-CoV-2 mRNA Vaccine Effectiveness in Health Care Workers by Dosing Interval and Time Since Vaccination: Test-Negative Design, British Columbia, Canada Open Forum Infectious Diseases |
| doi_str_mv |
10.1093/ofid/ofac178 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9vZmlkL29mYWMxNzg |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9vZmlkL29mYWMxNzg |
| institution |
DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 |
| imprint |
Oxford University Press (OUP), 2022 |
| imprint_str_mv |
Oxford University Press (OUP), 2022 |
| issn |
2328-8957 |
| issn_str_mv |
2328-8957 |
| language |
English |
| mega_collection |
Oxford University Press (OUP) (CrossRef) |
| match_str |
eladam2022sarscov2mrnavaccineeffectivenessinhealthcareworkersbydosingintervalandtimesincevaccinationtestnegativedesignbritishcolumbiacanada |
| publishDateSort |
2022 |
| publisher |
Oxford University Press (OUP) |
| recordtype |
ai |
| record_format |
ai |
| series |
Open Forum Infectious Diseases |
| source_id |
49 |
| title |
SARS-CoV-2 mRNA Vaccine Effectiveness in Health Care Workers by Dosing Interval and Time Since Vaccination: Test-Negative Design, British Columbia, Canada |
| title_unstemmed |
SARS-CoV-2 mRNA Vaccine Effectiveness in Health Care Workers by Dosing Interval and Time Since Vaccination: Test-Negative Design, British Columbia, Canada |
| title_full |
SARS-CoV-2 mRNA Vaccine Effectiveness in Health Care Workers by Dosing Interval and Time Since Vaccination: Test-Negative Design, British Columbia, Canada |
| title_fullStr |
SARS-CoV-2 mRNA Vaccine Effectiveness in Health Care Workers by Dosing Interval and Time Since Vaccination: Test-Negative Design, British Columbia, Canada |
| title_full_unstemmed |
SARS-CoV-2 mRNA Vaccine Effectiveness in Health Care Workers by Dosing Interval and Time Since Vaccination: Test-Negative Design, British Columbia, Canada |
| title_short |
SARS-CoV-2 mRNA Vaccine Effectiveness in Health Care Workers by Dosing Interval and Time Since Vaccination: Test-Negative Design, British Columbia, Canada |
| title_sort |
sars-cov-2 mrna vaccine effectiveness in health care workers by dosing interval and time since vaccination: test-negative design, british columbia, canada |
| topic |
Infectious Diseases Oncology |
| url |
http://dx.doi.org/10.1093/ofid/ofac178 |
| publishDate |
2022 |
| physical |
|
| description |
<jats:title>Abstract</jats:title>
<jats:sec>
<jats:title>Background</jats:title>
<jats:p>One- and two-dose mRNA vaccine effectiveness (VE) estimates against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by dosing interval and time since vaccination were assessed among healthcare workers (HCWs) in publicly funded acute and community (nonresidential) healthcare facilities in British Columbia, Canada.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Methods</jats:title>
<jats:p>A test-negative design was used with controls matched to cases (6:1) on epidemiological week of SARS-CoV-2 test date. mRNA vaccination was defined by receipt of the first dose ≥21 days or second dose ≥14 days before the test date. HCWs ≥18 years old tested for SARS-CoV-2 between epi-weeks 3 and 39 (January 17–October 2, 2021) were included, when varying dosing intervals and a mix of circulating variants of concern contributed, including Delta dominance provincially from epi-week 31 (August 1).</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results</jats:title>
<jats:p>Single- and two-dose analyses included 1265 and 1246 cases, respectively. The median follow-up period (interquartile range) was 49 (34–69) days for single-dose and 89 (61–123) days for two-dose recipients, with 12%, 31%, and 58% of second doses given 3–5, 6, or ≥7 weeks after the first. Adjusted mRNA VE against SARS-CoV-2 was 71% (95% CI, 66%–76%) for one dose and 90% (95% CI, 88%–92%) for two doses, similar to two heterologous mRNA doses (92%; 95% CI, 86%–95%). Two-dose VE remained &gt;80% at ≥28 weeks post–second dose. Two-dose VE was consistently 5%–7% higher with a ≥7-week vs 3–5-week interval between doses, but with overlapping confidence intervals.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusions</jats:title>
<jats:p>Among HCWs, we report substantial single-dose and strong and sustained two-dose mRNA vaccine protection, with the latter maintained for at least 7 months. These findings support a longer interval between doses, with global health and equity implications.</jats:p>
</jats:sec> |
| container_issue |
5 |
| container_start_page |
0 |
| container_title |
Open Forum Infectious Diseases |
| container_volume |
9 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792332112420929543 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T13:51:42.059Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=SARS-CoV-2+mRNA+Vaccine+Effectiveness+in+Health+Care+Workers+by+Dosing+Interval+and+Time+Since+Vaccination%3A+Test-Negative+Design%2C+British+Columbia%2C+Canada&rft.date=2022-05-01&genre=article&issn=2328-8957&volume=9&issue=5&jtitle=Open+Forum+Infectious+Diseases&atitle=SARS-CoV-2+mRNA+Vaccine+Effectiveness+in+Health+Care+Workers+by+Dosing+Interval+and+Time+Since+Vaccination%3A+Test-Negative+Design%2C+British+Columbia%2C+Canada&aulast=Skowronski&aufirst=Danuta+M&rft_id=info%3Adoi%2F10.1093%2Fofid%2Fofac178&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792332112420929543 |
| author | El Adam, Shiraz, Zou, Macy, Kim, Shinhye, Henry, Bonnie, Krajden, Mel, Skowronski, Danuta M |
| author_facet | El Adam, Shiraz, Zou, Macy, Kim, Shinhye, Henry, Bonnie, Krajden, Mel, Skowronski, Danuta M, El Adam, Shiraz, Zou, Macy, Kim, Shinhye, Henry, Bonnie, Krajden, Mel, Skowronski, Danuta M |
| author_sort | el adam, shiraz |
| container_issue | 5 |
| container_start_page | 0 |
| container_title | Open Forum Infectious Diseases |
| container_volume | 9 |
| description | <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>One- and two-dose mRNA vaccine effectiveness (VE) estimates against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by dosing interval and time since vaccination were assessed among healthcare workers (HCWs) in publicly funded acute and community (nonresidential) healthcare facilities in British Columbia, Canada.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>A test-negative design was used with controls matched to cases (6:1) on epidemiological week of SARS-CoV-2 test date. mRNA vaccination was defined by receipt of the first dose ≥21 days or second dose ≥14 days before the test date. HCWs ≥18 years old tested for SARS-CoV-2 between epi-weeks 3 and 39 (January 17–October 2, 2021) were included, when varying dosing intervals and a mix of circulating variants of concern contributed, including Delta dominance provincially from epi-week 31 (August 1).</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Single- and two-dose analyses included 1265 and 1246 cases, respectively. The median follow-up period (interquartile range) was 49 (34–69) days for single-dose and 89 (61–123) days for two-dose recipients, with 12%, 31%, and 58% of second doses given 3–5, 6, or ≥7 weeks after the first. Adjusted mRNA VE against SARS-CoV-2 was 71% (95% CI, 66%–76%) for one dose and 90% (95% CI, 88%–92%) for two doses, similar to two heterologous mRNA doses (92%; 95% CI, 86%–95%). Two-dose VE remained &gt;80% at ≥28 weeks post–second dose. Two-dose VE was consistently 5%–7% higher with a ≥7-week vs 3–5-week interval between doses, but with overlapping confidence intervals.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Among HCWs, we report substantial single-dose and strong and sustained two-dose mRNA vaccine protection, with the latter maintained for at least 7 months. These findings support a longer interval between doses, with global health and equity implications.</jats:p> </jats:sec> |
| doi_str_mv | 10.1093/ofid/ofac178 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9vZmlkL29mYWMxNzg |
| imprint | Oxford University Press (OUP), 2022 |
| imprint_str_mv | Oxford University Press (OUP), 2022 |
| institution | DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1 |
| issn | 2328-8957 |
| issn_str_mv | 2328-8957 |
| language | English |
| last_indexed | 2024-03-01T13:51:42.059Z |
| match_str | eladam2022sarscov2mrnavaccineeffectivenessinhealthcareworkersbydosingintervalandtimesincevaccinationtestnegativedesignbritishcolumbiacanada |
| mega_collection | Oxford University Press (OUP) (CrossRef) |
| physical | |
| publishDate | 2022 |
| publishDateSort | 2022 |
| publisher | Oxford University Press (OUP) |
| record_format | ai |
| recordtype | ai |
| series | Open Forum Infectious Diseases |
| source_id | 49 |
| spelling | El Adam, Shiraz Zou, Macy Kim, Shinhye Henry, Bonnie Krajden, Mel Skowronski, Danuta M 2328-8957 Oxford University Press (OUP) Infectious Diseases Oncology http://dx.doi.org/10.1093/ofid/ofac178 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>One- and two-dose mRNA vaccine effectiveness (VE) estimates against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by dosing interval and time since vaccination were assessed among healthcare workers (HCWs) in publicly funded acute and community (nonresidential) healthcare facilities in British Columbia, Canada.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>A test-negative design was used with controls matched to cases (6:1) on epidemiological week of SARS-CoV-2 test date. mRNA vaccination was defined by receipt of the first dose ≥21 days or second dose ≥14 days before the test date. HCWs ≥18 years old tested for SARS-CoV-2 between epi-weeks 3 and 39 (January 17–October 2, 2021) were included, when varying dosing intervals and a mix of circulating variants of concern contributed, including Delta dominance provincially from epi-week 31 (August 1).</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Single- and two-dose analyses included 1265 and 1246 cases, respectively. The median follow-up period (interquartile range) was 49 (34–69) days for single-dose and 89 (61–123) days for two-dose recipients, with 12%, 31%, and 58% of second doses given 3–5, 6, or ≥7 weeks after the first. Adjusted mRNA VE against SARS-CoV-2 was 71% (95% CI, 66%–76%) for one dose and 90% (95% CI, 88%–92%) for two doses, similar to two heterologous mRNA doses (92%; 95% CI, 86%–95%). Two-dose VE remained &gt;80% at ≥28 weeks post–second dose. Two-dose VE was consistently 5%–7% higher with a ≥7-week vs 3–5-week interval between doses, but with overlapping confidence intervals.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Among HCWs, we report substantial single-dose and strong and sustained two-dose mRNA vaccine protection, with the latter maintained for at least 7 months. These findings support a longer interval between doses, with global health and equity implications.</jats:p> </jats:sec> SARS-CoV-2 mRNA Vaccine Effectiveness in Health Care Workers by Dosing Interval and Time Since Vaccination: Test-Negative Design, British Columbia, Canada Open Forum Infectious Diseases |
| spellingShingle | El Adam, Shiraz, Zou, Macy, Kim, Shinhye, Henry, Bonnie, Krajden, Mel, Skowronski, Danuta M, Open Forum Infectious Diseases, SARS-CoV-2 mRNA Vaccine Effectiveness in Health Care Workers by Dosing Interval and Time Since Vaccination: Test-Negative Design, British Columbia, Canada, Infectious Diseases, Oncology |
| title | SARS-CoV-2 mRNA Vaccine Effectiveness in Health Care Workers by Dosing Interval and Time Since Vaccination: Test-Negative Design, British Columbia, Canada |
| title_full | SARS-CoV-2 mRNA Vaccine Effectiveness in Health Care Workers by Dosing Interval and Time Since Vaccination: Test-Negative Design, British Columbia, Canada |
| title_fullStr | SARS-CoV-2 mRNA Vaccine Effectiveness in Health Care Workers by Dosing Interval and Time Since Vaccination: Test-Negative Design, British Columbia, Canada |
| title_full_unstemmed | SARS-CoV-2 mRNA Vaccine Effectiveness in Health Care Workers by Dosing Interval and Time Since Vaccination: Test-Negative Design, British Columbia, Canada |
| title_short | SARS-CoV-2 mRNA Vaccine Effectiveness in Health Care Workers by Dosing Interval and Time Since Vaccination: Test-Negative Design, British Columbia, Canada |
| title_sort | sars-cov-2 mrna vaccine effectiveness in health care workers by dosing interval and time since vaccination: test-negative design, british columbia, canada |
| title_unstemmed | SARS-CoV-2 mRNA Vaccine Effectiveness in Health Care Workers by Dosing Interval and Time Since Vaccination: Test-Negative Design, British Columbia, Canada |
| topic | Infectious Diseases, Oncology |
| url | http://dx.doi.org/10.1093/ofid/ofac178 |